Literature DB >> 23077235

Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.

N E Kummer1, R S Feinn, D W Griffin, J C Nulsen, C A Benadiva, L L Engmann.   

Abstract

STUDY QUESTION: Are there factors predicting the number of total and mature oocytes retrieved after controlled ovarian hyperstimulation (COH) utilizing a gonadotropin-releasing hormone (GnRH) antagonist protocol and a GnRH agonist (GnRHa) to induce oocyte maturation? SUMMARY ANSWER: Peak estradiol (E₂) level, post-trigger LH and progesterone and the magnitude of LH rise are independent predictors of the total number of oocytes and mature oocytes retrieved. WHAT IS KNOWN ALREADY: Despite multiple follicular development in high responders, oocyte retrieval after a GnRHa trigger in a small subset of patients fails to obtain a substantial number of total oocytes or mature oocytes. STUDY DESIGN, SIZE AND DURATION: A retrospective chart review of all autologous and oocyte donation cycles utilizing a GnRHa antagonist protocol where GnRHa was used for the induction of oocyte maturation between 1 April 2003 and 31 December 2011. PARTICIPANTS/MATERIALS, SETTING AND METHODS: A total of 508 autologous and donor IVF/ICSI cycles utilizing a GnRH antagonist protocol for COH and GnRHa for the induction of oocyte maturation at a university-based tertiary fertility center. MAIN RESULTS AND THE ROLE OF CHANCE: Peak E₂ on the day of trigger (r = 0.19, P < 0.001), post-trigger LH (r = 0.12, P = 0.009) and progesterone (r = 0.47, P < 001) and LH rise (r = 0.18, P < 0.001) all positively correlated with the number of total and mature oocytes retrieved. The true incidence of empty follicle syndrome was 1.4% (7/508). There was no post-trigger LH or progesterone cut-off value for the prediction of oocyte yield. However, all cases of empty follicle syndrome occurred in patients with post-trigger LH <15 IU/l and P ≤ 3.5 ng/ml. The findings of this study may also be due to chance since it was a retrospective study and not prospectively designed. LIMITATION, REASONS FOR CAUTION: This is a retrospective chart review and therefore subject to bias. Serum hormone measurements were performed between 8 and 12 h after GnRHa trigger rather than a standardized time period following trigger administration. Therefore, peak levels of LH may have been missed due to the short ascending limb of LH rise lasting approximately 4 h after GnRHa trigger. WIDER IMPLICATIONS OF THE
FINDINGS: The results of this study can be generalized to high responders utilizing a GnRH antagonist protocol for COH and a GnRHa for the induction of oocyte maturation. The use of alternative stimulation regimens or medications will limit the ability to generalize the results of this study to other populations. STUDY FUNDING/COMPETING INTEREST(S): This study was not funded, and there are no conflicts of interest. TRIAL REGISTRATION NUMBER: n/a.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23077235     DOI: 10.1093/humrep/des361

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  21 in total

1.  Differences in ovarian hormones in relation to parity and time since last birth.

Authors:  Emily S Barrett; Lauren E Parlett; Gayle C Windham; Shanna H Swan
Journal:  Fertil Steril       Date:  2014-03-28       Impact factor: 7.329

2.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

Review 3.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

4.  Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series.

Authors:  Bülent Gülekli; Funda Göde; Zerrin Sertkaya; Ahmet Zeki Işık
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-03-01

5.  Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Anuja Dokras
Journal:  Fertil Steril       Date:  2014-11-06       Impact factor: 7.329

Review 6.  Prediction, assessment, and management of suboptimal GnRH agonist trigger: a systematic review.

Authors:  Hadas Ganer Herman; Eran Horowitz; Yossi Mizrachi; Jacob Farhi; Arieh Raziel; Ariel Weissman
Journal:  J Assist Reprod Genet       Date:  2022-03-19       Impact factor: 3.412

7.  GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Ivy Maina; Clarisa Gracia; Anuja Dokras
Journal:  J Assist Reprod Genet       Date:  2016-06-27       Impact factor: 3.412

8.  Oocyte competence is independent of the ovulation trigger adopted: a large observational study in a setting that entails vitrified-warmed single euploid blastocyst transfer.

Authors:  Danilo Cimadomo; Alberto Vaiarelli; Cecilia Petriglia; Gemma Fabozzi; Susanna Ferrero; Mauro Schimberni; Cindy Argento; Silvia Colamaria; Maddalena Giuliani; Nicolò Ubaldi; Laura Rienzi; Filippo Maria Ubaldi
Journal:  J Assist Reprod Genet       Date:  2021-03-04       Impact factor: 3.357

9.  Comparison of hCG triggering versus hCG in combination with a GnRH agonist: a prospective randomized controlled trial.

Authors:  W Decleer; K Osmanagaoglu; B Seynhave; S Kolibianakis; B Tarlatzis; P Devroey
Journal:  Facts Views Vis Obgyn       Date:  2014

10.  Repeat Dose of Gonadotropin-releasing Hormone Agonist Trigger in Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization Cycles Provides a Better Cycle Outcome - A proof-of-concept Study.

Authors:  Krishna Deepika; Pookilath Baiju; Praneesh Gautham; Rathore Suvarna; Vohra Arveen; Rao Kamini
Journal:  J Hum Reprod Sci       Date:  2017 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.